No matter how cynical the overall market is, Amylyx Pharmaceuticals Inc (AMLX) performance over the last week is recorded -3.08%

On Tuesday, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) opened lower -4.14% from the last session, before settling in for the closing price of $8.21. Price fluctuations for AMLX have ranged from $1.76 to $8.72 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales drop of Healthcare Sector giant was -78.71%. Company’s average yearly earnings per share was noted 59.57% at the time writing. With a float of $65.31 million, this company’s outstanding shares have now reached $89.08 million.

Let’s determine the extent of company efficiency that accounts for 123 employees. In terms of profitability, gross margin is 775.71%, operating margin of 16317.06%, and the pretax margin is 17255.66%.

Amylyx Pharmaceuticals Inc (AMLX) Breakdown of a Key Holders of the stock

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Amylyx Pharmaceuticals Inc is 26.74%, while institutional ownership is 80.20%. The most recent insider transaction that took place on Mar 31 ’25, was worth 37,806. In this transaction Chief Financial Officer of this company sold 10,896 shares at a rate of $3.47, taking the stock ownership to the 290,988 shares. Before that another transaction happened on Mar 31 ’25, when Company’s Chief Medical Officer sold 12,425 for $3.47, making the entire transaction worth $43,082. This insider now owns 194,375 shares in total.

Amylyx Pharmaceuticals Inc (AMLX) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 59.57% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.27% during the next five years compared to -78.71% drop over the previous five years of trading.

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators

Check out the current performance indicators for Amylyx Pharmaceuticals Inc (AMLX). In the past quarter, the stock posted a quick ratio of 12.05.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.49 in one year’s time.

Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)

Looking closely at Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), its last 5-days average volume was 1.48 million, which is a jump from its year-to-date volume of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 68.72%.

During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 86.11%, which indicates a significant increase from 69.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.54 in the past 14 days, which was higher than the 0.39 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $5.96, while its 200-day Moving Average is $4.63. However, in the short run, Amylyx Pharmaceuticals Inc’s stock first resistance to watch stands at $8.11. Second resistance stands at $8.34. The third major resistance level sits at $8.48. If the price goes on to break the first support level at $7.74, it is likely to go to the next support level at $7.60. Now, if the price goes above the second support level, the third support stands at $7.37.

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats

There are currently 89,141K shares outstanding in the company with a market cap of 701.54 million. Presently, the company’s annual sales total 87,370 K according to its annual income of -301,740 K. Last quarter, the company’s sales amounted to -660 K and its income totaled -37,550 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.